Compass Therapeutics Gross Profit

As of the most recent data (June 2026), CMPX shows a gross profit of $0. That compares with $-370K in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of $67B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CMPX's gross profit is now $0 (was $-370K) — a 100.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Compass Therapeutics is outperforming or lagging.

The Healthcare sector average gross profit is about $67B. Compass Therapeutics is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how CMPX stacks up against individual peers as well.

Tracking CMPX's gross profit over time shows whether Compass Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $-370K in the prior-year period — up 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Compass Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $0) with ownership activity and broader fundamentals.